Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Pharvaris N.V. PHVS
$8.33
+$0.41 (4.98%)
На 18:04, 12 мая 2023
+176.11%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
302319510.00000000
-
week52high
27.50
-
week52low
1.77
-
Revenue
0
-
P/E TTM
-11
-
Beta
-4.60812200
-
EPS
-2.44000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 10:59
Описание компании
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Pharvaris: Focused Pipeline On Hereditary Angioedema
Seeking Alpha
13 янв 2023 г. в 08:00
Pharvaris has a pipeline fully focused on HAE. Their molecule has a differentiated value proposition.
Pharvaris shares soar on positive top-line Phase 2 data from RAPIDe-1 study as it releases 3Q results
Proactive Investors
08 дек 2022 г. в 11:34
Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, has announced positive top-line data from its RAPIDe-1 Phase 2 clinical study, sending its shares soaring in early trade. Releasing the results alongside its third-quarter financials, the Zug, Switzerland-based company said the data demonstrates statistically significant results of PHVS416 as an oral on-demand treatment for HAE attacks.
Why Is Pharvaris (PHVS) Stock Up 62% Today?
InvestorPlace
08 дек 2022 г. в 10:37
Pharvaris (NASDAQ: PHVS ) stock is heading higher on Thursday following the release of positive results from a Phase 2 clinical study. That clinical trial covers PHVS416, which is an oral treatment for hereditary angioedema ( HAE ) attacks.
Why Pharvaris Stock Crashed — And Why At Least One Analyst Isn't Worried
Investors Business Daily
22 авг 2022 г. в 12:18
Biotech stock Pharvaris plummeted Monday after the Food and Drug Administration placed a pair of its clinical studies on hold. The post Why Pharvaris Stock Crashed — And Why At Least One Analyst Isn't Worried appeared first on Investor's Business Daily.
Pharvaris to Participate in Upcoming April Investor Conferences
GlobeNewsWire
06 апр 2022 г. в 16:10
ZUG, Switzerland, April 06, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today announced that management will participate in two upcoming investor conferences in April: